Page last updated: 2024-12-05

imipramine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Imipramine hydrochloride is a tricyclic antidepressant (TCA) medication. It was first synthesized in 1957 and approved for medical use in 1961. Imipramine hydrochloride is thought to work by increasing the levels of the neurotransmitters serotonin and norepinephrine in the brain. It is primarily used to treat major depressive disorder and other mental health conditions, such as generalized anxiety disorder and panic disorder. Imipramine hydrochloride is effective in treating these conditions, but it can have several side effects, including dry mouth, constipation, blurred vision, drowsiness, and weight gain. It is important to note that imipramine hydrochloride should not be taken by people with certain medical conditions, such as glaucoma, heart disease, and liver disease. Imipramine hydrochloride is a widely studied medication, and researchers are continuing to investigate its potential benefits and risks. Recent studies have focused on the use of imipramine hydrochloride in the treatment of other conditions, such as chronic pain and irritable bowel syndrome.'

Cross-References

ID SourceID
PubMed CID8228
CHEMBL ID1692
CHEBI ID5882
SCHEMBL ID41765
MeSH IDM0330160

Synonyms (168)

Synonym
feinalmin
5h-dibenz[b, 5-[3-(dimethylamino)propyl]-10,11-dihydro-, monohydrochloride
co cap imipramine 25
imilanyle
pertofram
g 22150
pryleugan
melipramine hydrochloride
iprogen
antideprin hydrochloride
tofranile
persamine
presamine
g 22355
teperine
wln: t c676 bn & t & j b3n1 & 1 & gh
n-(.gamma.-dimethylaminopropyl)iminodibenzyl hydrochloride
imp hydrochloride
chimoreptin
nsc-114900
sk-pramine hcl
5h-dibenz[b, 10,11-dihydro-n,n-dimethyl-, monohydrochloride
5h-dibenz[b, 10,11-dihydro-5-[3-(dimethylamino)propyl]-, hydrochloride
ia-pram
melipramine hcl
5-(3-dimethylaminopropyl)-10,f)azepine hydrochloride
n-(3-dimethylaminopropyl)iminodibenzyl hydrochloride
nsc114900
imipramine monohydrochloride
AC-7587
MLS001146891
5h-dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-n,n-dimethyl-, monohydrochloride
g-22355
MLS000028430 ,
EU-0100702
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethylpropan-1-amine hydrochloride
CHEBI:5882 ,
imipramine hydrochloride, >=99% (tlc)
efuranol
imipramini
pramine
sk-pramine hydrochloride
n-(gamma-dimetilaminopropil)-iminodibenzile cloridrato [italian]
imipramine hydrochloride [jan]
vionyl
einecs 204-030-7
chrytemin
n-(gamma-dimethylaminopropyl)iminodibenzyl hydrochloride
imipramine hcl
odeoxil
psicopramine
imidol
imipramini hydrochloridum
5h-dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)propyl)-, hydrochloride
fujisawa
5-(3-dimethylaminopropyl)-10,11-dihydro-5h-dibenz(b,f)azepine hydrochloride
deprinol
5h-dibenz(b,f)azepine, 5-(3-(dimethylamino)propyl)-10,11-dihydro-, monohydrochloride
5h-dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-n,n-dimethyl-, monohydrochloride
thymopramin
nsc 114900
tipramine
5-(3-(dimethylamino)propyl)-10,11-dihydro-5h-dibenz(b,f)azepine monohydrochloride
dynazina
venefon
5-(3-dimethylaminopropyl)-10,11-dihydro-5h-dibenz-[b,f]-azepine, hydrochloride
PRESTWICK_277
C07982
113-52-0
imipramine hydrochloride
imipramine hydrochloride, bioxtra, >=99% (tlc)
D00815
imipramine hydrochloride (jp17/usp)
NCGC00094054-02
NCGC00094054-03
NCGC00024253-05
smr000058388
SPECTRUM1500348
NCGC00094054-05
NCGC00094054-04
NCGC00094054-01
MLS002222195
I 7379
imipramine hydrochloride rs
CHEMBL1692
HMS1568O05
HMS1920F17
cpd000058388
imipramine hydrochloride [usp:jan]
imipram
5h-dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-n,n-dimethyl-, hydrochloride (1:1)
n-(gamma-dimetilaminopropil)-iminodibenzile cloridrato
bke5q1j60u ,
unii-bke5q1j60u
tox21_301417
dtxsid7040738 ,
NCGC00255651-01
dtxcid5020738
nsc-757074
nsc757074
pharmakon1600-01500348
S4377
CCG-40208
ST50985122 ,
FT-0670318
FT-0631652
LP00702
AKOS015895330
imipramine hydrochloride [mart.]
imipramine hydrochloride [orange book]
imipramine hydrochloride [usp monograph]
imipramine hydrochloride [who-ip]
imipramine hydrochloride [mi]
imipramine hydrochloride [vandf]
imipramine hydrochloride [usp-rs]
imipramine hydrochloride [usp impurity]
imipramine hydrochloride [who-dd]
imipramini hydrochloridum [who-ip latin]
imipramine hydrochloride [ep monograph]
NC00570
SCHEMBL41765
KS-1072
XZZXIYZZBJDEEP-UHFFFAOYSA-N
tox21_500702
NCGC00261387-01
REGID_FOR_CID_8228
Q-200878
surecn41766
10,11-dihydro-n,n-dimethyl-5h-dibenzo[b,f]azepine-5-propanamine hydrochloride
I0971
5-[3-(dimethylamino)propyl]-10,11-dihydro-5h-dibenzo[b,f]azepine hydrochloride
imipraminehcl
OPERA_ID_319
mfcd00012669
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethylpropan-1-amine;hydrochloride
J-002975
imipramine (hydrochloride)
HY-B1490
CS-6180
SR-01000003064-2
sr-01000003064
imipramine hydrochloride, united states pharmacopeia (usp) reference standard
imipramine hydrochloride, european pharmacopoeia (ep) reference standard
imipramine hydrochloride, sigma reference standard
imipramine for system suitability, european pharmacopoeia (ep) reference standard
imipramine hydrochloride, pharmaceutical secondary standard; certified reference material
imipramine hydrochloride 1.0 mg/ml in methanol (as free base)
SR-01000003064-7
SW196582-4
Z1546610478
Q27106923
EN300-123017
(3-{2-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine hydrochloride
imipramine for system suitability
BI164574
3-(10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethyl-1-propanamine hydrochloride
SY113894
3-(10,11-dihydro-5h-dibenzo(b,f)azepin-5-yl)-n,n-dimethylpropylamine monohydrochloride
imipramine hydrochloride (ep monograph)
imipramine hydrochloride (usp:jan)
3-(10,11-dihydro-5h-dibenzo(b,f)azepin-5-yl)-n,n-dimethylpropan-1-aminium chloride
imipramine hydrochloride (usp monograph)
imipramine hydrochloride (mart.)
imipramine hydrochloride (usp impurity)
imipramine hydrochloride (usp-rs)
3-(10,11-dihydro-5h-dibenzo(b,f)azepin-5-yl)-n,n-dimethylpropan-1-amine hydrochloride
imipramine.hcl, 1mg/ml in methanol
imipramine.hcl

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antidepressantAntidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (38)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency9.14980.003245.467312,589.2998AID2517; AID2573
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
glp-1 receptor, partialHomo sapiens (human)Potency1.77830.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency26.67950.100020.879379.4328AID588453
RAR-related orphan receptor gammaMus musculus (house mouse)Potency45.88420.006038.004119,952.5996AID1159521; AID1159523
TDP1 proteinHomo sapiens (human)Potency18.28750.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency6.93900.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency19.95260.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency41.22450.000221.22318,912.5098AID1259243; AID1259247; AID743036; AID743054
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency51.52020.000657.913322,387.1992AID1259377; AID1259378
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency19.49380.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency32.50710.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency25.42250.000817.505159.3239AID1159531; AID588546
farnesoid X nuclear receptorHomo sapiens (human)Potency44.66840.375827.485161.6524AID588526
pregnane X nuclear receptorHomo sapiens (human)Potency6.58430.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency32.75940.000229.305416,493.5996AID588513; AID743069; AID743075; AID743078; AID743079
67.9K proteinVaccinia virusPotency22.38720.00018.4406100.0000AID720579
glucocerebrosidaseHomo sapiens (human)Potency25.11890.01268.156944.6684AID2101
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency31.62280.001024.504861.6448AID588534
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency21.87240.001019.414170.9645AID743191
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency40.39730.035520.977089.1251AID504332
thyroid stimulating hormone receptorHomo sapiens (human)Potency53.13920.001628.015177.1139AID1224843; AID1259385; AID1259395
thyrotropin-releasing hormone receptorHomo sapiens (human)Potency38.90180.154917.870243.6557AID1346891
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency7.33870.057821.109761.2679AID1159526; AID1159528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency75.686323.934123.934123.9341AID1967
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency5.61170.010039.53711,122.0200AID588545; AID588547
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency11.22020.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency18.03510.000323.4451159.6830AID743065; AID743067
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency35.48134.466824.832944.6684AID651749
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency24.33650.000627.21521,122.0200AID743202
gemininHomo sapiens (human)Potency9.23610.004611.374133.4983AID504364; AID624296
survival motor neuron protein isoform dHomo sapiens (human)Potency2.50640.125912.234435.4813AID1458
M-phase phosphoprotein 8Homo sapiens (human)Potency0.14130.177824.735279.4328AID488949
transient receptor potential cation channel subfamily V member 1Homo sapiens (human)Potency19.95260.09120.09120.0912AID488979
lamin isoform A-delta10Homo sapiens (human)Potency14.12540.891312.067628.1838AID1487
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency19.95260.316212.765731.6228AID881
Cellular tumor antigen p53Homo sapiens (human)Potency3.85710.002319.595674.0614AID651631
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency19.95260.00638.235039.8107AID881
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (144)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (41)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (91)

Assay IDTitleYearJournalArticle
AID114146Antidepressant activity using yohimbine potentiation test in mice1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
A new nontricyclic antidepressant agent. Synthesis and activity of N-[trans-2-(dimethylamino)cyclopentyl]-N-(3,4-dichlorophenyl)propanamide and related compounds.
AID1220793Ratio of drug level in blood to plasma in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1137414Antidepressant activity in ip dosed albino CF1 mouse assessed as potentiation of gamma-butyrolactone-induced sleep1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID1220792Ratio of drug level in blood to plasma in dog2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1220785Fraction unbound in rat plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1137410Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against pentylenetetrazole-induced clonic convulsions1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID119563Antihypoxic effect by the survival time (SVT) in mice at a dose of 30 mg/kg administered subcutaneously in mice; NT indicates not tested1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 1. Synthesis and pharmacology of 1-amino-7-hydroxyindan derivatives.
AID1137413Anticonvulsant activity in ip dosed albino CF1 mouse assessed as inhibition of bicucullin-induced tonic extensor convulsions1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID1196229Antidepressant activity in Swiss albino mouse assessed as reduction of immobility time at 10 mg/kg, ip measured during last 4 mins of a 6 mins test session by forced swim (porsolt) test2015European journal of medicinal chemistry, Mar-06, Volume: 92Towards novel 5-HT7versus 5-HT1A receptor ligands among LCAPs with cyclic amino acid amide fragments: design, synthesis, and antidepressant properties. Part II.
AID1220796Drug metabolism in bile duct-cannulated rat assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1220791Ratio of drug level in blood to plasma in monkey2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1220795Plasma clearance in po dosed human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1204320Antidepressant-like activity in ip dosed Swiss mouse assessed as reduction in immobility time administered 30 mins before test2015European journal of medicinal chemistry, Jun-05, Volume: 97Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity.
AID1147936Reversal of reserpine-induced ptosis in po dosed mouse1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Adrenergic sulfonanilides. 4. Centrally active beta-adrenergic agonists.
AID1123818Antidepressant activity in po dosed ICEM:CET (SPF Caw) mouse assessed as antagonism of reserpine-induced blepharospasm administered via gavage 30 mins before reserpine challenge measured 1 hr after reserpine treatment1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Azetidine derivatives of tricyclic antidepressant agents.
AID1137419Potentiation of apomorphine-induced gnawing in ip dosed albino CF1 mouse1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID114145Antidepressant activity using oxotremorine antagonism test in mice1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
A new nontricyclic antidepressant agent. Synthesis and activity of N-[trans-2-(dimethylamino)cyclopentyl]-N-(3,4-dichlorophenyl)propanamide and related compounds.
AID1220801Drug metabolism in bile duct-cannulated dog assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1220797Volume of distribution at steady state in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1220790Ratio of drug level in blood to plasma in rat2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1137418Inhibition of oxotremorine-induced hypothermia in ip dosed albino CF1 mouse1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID1220799Drug metabolism in gallbladder-cannulated mouse assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID119179Time of recovery of righting reflux (RRT) in seconds was measured after administration of 100 mg/kg orally in mice for the promotional effect on recovery from coma1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 1. Synthesis and pharmacology of 1-amino-7-hydroxyindan derivatives.
AID1220789Ratio of drug level in blood to plasma in mouse2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID187167Inhibition of serotonin (5-HT) uptake into rat brain synaptosomes1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin.
AID114144Antidepressant activity using apomorphine potentiation test in mice1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
A new nontricyclic antidepressant agent. Synthesis and activity of N-[trans-2-(dimethylamino)cyclopentyl]-N-(3,4-dichlorophenyl)propanamide and related compounds.
AID119554Antihypoxic effect tested by the survival time (SVT) in mice at a dose of 100 mg/kg1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 1. Synthesis and pharmacology of 1-amino-7-hydroxyindan derivatives.
AID1123822Orientative acute toxicity in po dosed ICEM:CET (SPF Caw) mouse administered via gavage measured for 60 mins after drug dosing by Irwin's test1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Azetidine derivatives of tricyclic antidepressant agents.
AID646433Antidepressant activity in Swiss albino mouse assessed as reduction in immobility time at 10 mg/kg measured for 4 mins by forced swim test2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor-5-HT1A/5-HT2A/5-HT7 and D2/D3/D4-agents: the synthesis and pharmacological evaluation.
AID1123820Antidepressant activity in po dosed ICEM:CET (SPF Caw) mouse assessed as antagonism of reserpine-induced hypothermia administered via gavage 30 mins before reserpine challenge measured 4 hrs after reserpine treatment1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Azetidine derivatives of tricyclic antidepressant agents.
AID1220787Fraction unbound in dog plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1137411Hypothermic activity in ip dosed albino CF1 mouse assessed as effect on body temperature measured after 45 mins1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID119258Time of recovery of spontaneous movement (SMT) in seconds was measured after administration of 100 mg/kg orally in mice for the promotional effect on recovery from coma1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Novel cerebroprotective agents with central nervous system stimulating activity. 1. Synthesis and pharmacology of 1-amino-7-hydroxyindan derivatives.
AID646432Antidepressant activity in Swiss albino mouse assessed as reduction in immobility time at 20 mg/kg measured for 4 mins by forced swim test2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor-5-HT1A/5-HT2A/5-HT7 and D2/D3/D4-agents: the synthesis and pharmacological evaluation.
AID127692Inhibition of tetrabenazine (TBZ)-induced ptosis in mice (administered ip)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1220800Drug metabolism in bile duct-cannulated monkey assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID187166Inhibition of dopamine (DA) uptake into rat brain synaptosomes1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin.
AID1137416Inhibition of amphetamine aggregation toxicity in ip dosed albino CF1 mouse compound administered 1 hr prior to challenge measured after 2 hrs1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID1220783Drug metabolism in human assessed as glucuronide concentration in bile and urine2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1204347Toxicity in Swiss mouse assessed as spontaneous locomotor activity at 5 to 20 mg/kg, ip measured during 2 to 6 mins2015European journal of medicinal chemistry, Jun-05, Volume: 97Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1220786Fraction unbound in monkey plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1147935Inhibition of reserpine-induced ptosis in po dosed mouse1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Adrenergic sulfonanilides. 4. Centrally active beta-adrenergic agonists.
AID1137417Potentiation of yohimbine toxicity in ip dosed aggregated albino CF1 mouse1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID1123821Anticonvulsant activity in po dosed ICEM:CET (SPF Caw) mouse assessed as antagonism of pentylenetetrazole-induced flexor-extensor tonic convulsions administered via gavage 30 mins before pentylenetetrazole challenge1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Azetidine derivatives of tricyclic antidepressant agents.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1220798Half life in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID187165Inhibition of norepinephrine (NE) into rat brain synaptosomes1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin.
AID1137412Inhibition of apomorphine-induced cage climbing in ip dosed albino CF1 mouse compound administered prior to challenge measured for 5 mins after 5 mins of challenge1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID127690Inhibition of tetrabenazine (TBZ)-induced depression of motor activity (MA) in mice (administered ip)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin.
AID1137415Reduction of hypoxic stress in ip dosed albino CF1 mouse assessed as prolongation of hypoxic survival time1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity.
AID1220788Fraction unbound in human plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1220794Plasma clearance in human2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID1220784Fraction unbound in mouse plasma by ultracentrifugation method2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (19.23)18.7374
1990's1 (3.85)18.2507
2000's3 (11.54)29.6817
2010's15 (57.69)24.3611
2020's2 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 65.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index65.29 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index5.31 (4.65)
Search Engine Demand Index104.74 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (65.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (96.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]